Last reviewed · How we verify
Iodopyrrole (IODOL)
Iodopyrrole (generic name: IODOL) is a drug. It is currently in Phase 3 development.
Iodopyrrole is a small molecule that binds to a specific target, altering its function to produce a therapeutic effect.
Iodopyrrole (IODOL) is a small molecule modality developed by an unknown entity, currently owned by an unknown entity. Its target and drug class are unknown, and it has not been approved by the FDA for any indications. The commercial status of IODOL is unclear, and it is not known whether it is patented or available as a generic. Further research is needed to determine its safety profile and potential therapeutic applications. As a result, IODOL is not a recognized treatment option at this time.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IODOL |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Mechanism of action
Imagine a key that fits into a lock. Iodopyrrole is like that key, designed to fit into a specific lock (target) on a cell. When it binds, it can turn the lock's function on or off, which can help treat a disease.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iodopyrrole CI brief — competitive landscape report
- Iodopyrrole updates RSS · CI watch RSS
Frequently asked questions about Iodopyrrole
What is Iodopyrrole?
How does Iodopyrrole work?
What is the generic name of Iodopyrrole?
What development phase is Iodopyrrole in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing